NASDAQ:TRILTrillium Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.00 +0.23 (+2.96 %) (As of 06/2/2020 10:16 AM ET) Add Compare Share Today's Range$7.92Now: $8.00▼$8.3650-Day Range$3.96MA: $5.50▼$7.0552-Week Range$0.24Now: $8.00▼$7.97Volume53,227 shsAverage Volume2.64 million shsMarket Capitalization$667.52 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingTrillium Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Trillium Therapeutics has a potential upside of 23.5% from its current price of $8.10.Amount of Analyst CoverageTrillium Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesTrillium Therapeutics has received 291 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrillium Therapeutics has received 197 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrillium Therapeutics has received 59.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote “Outperform” if you believe TRIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTrillium Therapeutics does not currently pay a dividend.Dividend GrowthTrillium Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trillium Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions73.21% of the stock of Trillium Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trillium Therapeutics are expected to grow in the coming year, from ($0.69) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trillium Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trillium Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRIL Previous Symbol CUSIPN/A CIK1616212 Webwww.trilliumtherapeutics.com Phone416-595-0627Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales5,562.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.86) per share Price / Book-9.30Profitability EPS (Most Recent Fiscal Year)($1.38) Net Income$-41,620,000.00 Net MarginsN/A Return on Equity-371.12% Return on Assets-50.63%Miscellaneous EmployeesN/A Outstanding Shares83,440,000Market Cap$667.52 million Next Earnings Date8/11/2020 (Estimated) OptionableOptionable NASDAQ:TRIL Rates by TradingView Receive TRIL News and Ratings via Email Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions How has Trillium Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 56.1% and is now trading at $8.10. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Trillium Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trillium Therapeutics. When is Trillium Therapeutics' next earnings date? Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Trillium Therapeutics. How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc (NASDAQ:TRIL) released its earnings results on Friday, May, 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.14. View Trillium Therapeutics' earnings history. What price target have analysts set for TRIL? 3 equities research analysts have issued twelve-month price targets for Trillium Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Trillium Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 23.5% from the stock's current price. View analysts' price targets for Trillium Therapeutics. Has Trillium Therapeutics been receiving favorable news coverage? News coverage about TRIL stock has been trending very positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutTrillium Therapeutics. Who are some of Trillium Therapeutics' key competitors? Some companies that are related to Trillium Therapeutics include Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Passage Bio (ZNTL), Corcept Therapeutics (CORT), Epizyme (EPZM), Xencor (XNCR), Zymeworks (ZYME) and Heron Therapeutics (HRTX). View all competitors. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Opko Health (OPK), TG Therapeutics (TGTX), Karyopharm Therapeutics (KPTI) and VBI Vaccines (VBIV). Who are Trillium Therapeutics' key executives? Trillium Therapeutics' management team includes the following people: Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & DirectorMr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)Dr. Robert Uger, Chief Scientific OfficerDr. Penka Petrova, Chief Devel. OfficerDr. Yaping Shou, Chief Medical Officer What is Trillium Therapeutics' stock symbol? Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL." Who are Trillium Therapeutics' major shareholders? Trillium Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include VR Adviser LLC (8.21%), RA Capital Management L.P. (7.69%), NEA Management Company LLC (6.94%), Deutsche Bank AG (3.00%), Frazier Management LLC (2.96%) and Alliancebernstein L.P. (2.86%). Which institutional investors are selling Trillium Therapeutics stock? TRIL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Which institutional investors are buying Trillium Therapeutics stock? TRIL stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, RA Capital Management L.P., NEA Management Company LLC, Deutsche Bank AG, Frazier Management LLC, Alliancebernstein L.P., Vivo Capital LLC, and Fairmount Funds Management LLC. How do I buy shares of Trillium Therapeutics? Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Trillium Therapeutics' stock price today? One share of TRIL stock can currently be purchased for approximately $8.10. How big of a company is Trillium Therapeutics? Trillium Therapeutics has a market capitalization of $675.86 million and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. What is Trillium Therapeutics' official website? The official website for Trillium Therapeutics is www.trilliumtherapeutics.com. How can I contact Trillium Therapeutics? Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
